These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25213022)

  • 41. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
    Itoi T; Sofuni A; Fukushima N; Itokawa F; Tsuchiya T; Kurihara T; Moriyasu F; Tsuchida A; Kasuya K
    J Gastroenterol; 2007 May; 42(5):389-94. PubMed ID: 17530364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RRM2 is a potential prognostic biomarker with functional significance in glioma.
    Sun H; Yang B; Zhang H; Song J; Zhang Y; Xing J; Yang Z; Wei C; Xu T; Yu Z; Xu Z; Hou M; Ji M; Zhang Y
    Int J Biol Sci; 2019; 15(3):533-543. PubMed ID: 30745840
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
    Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
    Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy.
    Li J; Pang J; Liu Y; Zhang J; Zhang C; Shen G; Song L
    Oncol Rep; 2018 Jul; 40(1):355-360. PubMed ID: 29749541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
    Morikawa T; Hino R; Uozaki H; Maeda D; Ushiku T; Shinozaki A; Sakatani T; Fukayama M
    Hum Pathol; 2010 Dec; 41(12):1742-8. PubMed ID: 20825972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas.
    Bjørklund SS; Kristensen VN; Seiler M; Kumar S; Alnæs GI; Ming Y; Kerrigan J; Naume B; Sachidanandam R; Bhanot G; Børresen-Dale AL; Ganesan S
    BMC Cancer; 2015 Jul; 15():524. PubMed ID: 26183823
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.
    Shah KN; Mehta KR; Peterson D; Evangelista M; Livesey JC; Faridi JS
    Mol Cancer Res; 2014 Mar; 12(3):394-407. PubMed ID: 24362250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction.
    Li ZN; Shu Y; Chen CG; Li XQ; Li MY; Zhao XH; Wang S; Li J
    Biochem Biophys Res Commun; 2020 Jul; 528(3):554-560. PubMed ID: 32505349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The SNHG16/miR-30a axis promotes breast cancer cell proliferation and invasion by regulating RRM2.
    Du SM
    Neoplasma; 2020 May; 67(3):567-575. PubMed ID: 32122142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib‑based therapy.
    Liu C; Li Y; Hu R; Han W; Gao S
    Oncol Rep; 2019 Aug; 42(2):571-580. PubMed ID: 31233186
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
    Yndestad S; Austreid E; Svanberg IR; Knappskog S; Lønning PE; Eikesdal HP
    Oncotarget; 2017 Jun; 8(25):41227-41241. PubMed ID: 28476032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
    Bianchini G; Qi Y; Alvarez RH; Iwamoto T; Coutant C; Ibrahim NK; Valero V; Cristofanilli M; Green MC; Radvanyi L; Hatzis C; Hortobagyi GN; Andre F; Gianni L; Symmans WF; Pusztai L
    J Clin Oncol; 2010 Oct; 28(28):4316-23. PubMed ID: 20805453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer.
    Zhang X; Su X; Guo Z; Jiang X; Li X
    J Clin Lab Anal; 2020 Jul; 34(7):e23272. PubMed ID: 32187743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness.
    Duxbury MS; Whang EE
    Biochem Biophys Res Commun; 2007 Mar; 354(1):190-6. PubMed ID: 17222798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β‑catenin signaling pathway.
    Liu X; Peng J; Zhou Y; Xie B; Wang J
    Mol Med Rep; 2019 Sep; 20(3):2159-2166. PubMed ID: 31322175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
    Coutant C; Rouzier R; Qi Y; Lehmann-Che J; Bianchini G; Iwamoto T; Hortobagyi GN; Symmans WF; Uzan S; Andre F; de Thé H; Pusztai L
    Clin Cancer Res; 2011 Apr; 17(8):2591-601. PubMed ID: 21248301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
    Alles MC; Gardiner-Garden M; Nott DJ; Wang Y; Foekens JA; Sutherland RL; Musgrove EA; Ormandy CJ
    PLoS One; 2009; 4(3):e4710. PubMed ID: 19270750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
    Sato A; Takagi K; Miki Y; Yoshimura A; Hara M; Ishida T; Sasano H; Suzuki T
    Histol Histopathol; 2019 Dec; 34(12):1365-1375. PubMed ID: 31149728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.